<DOC>
	<DOC>NCT00445770</DOC>
	<brief_summary>The purpose of this study is to examine the effects of etanercept (10 mg and 25 mg) compared with methotrexate (up to 8 mg per week) on the slowing of joint destruction.</brief_summary>
	<brief_title>Study Evaluating the Efficacy and Safety of Etanercept and Methotrexate in Japanese Subjects With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Must be Japanese and live in Japan Must be age 20 to 75 years Diagnosed less than or equal to 10 years from time of first visit Anyone who has received etanercept or TNFinhibitors such as infliximab or adalimumab in the past Patient with other rheumatic diseases or conditions that could predispose the patient to infection Pregnant or lactating women</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Arthritis</keyword>
</DOC>